Actinium Pharmaceuticals (ATNM) News Today $1.58 +0.09 (+6.04%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$1.60 +0.02 (+1.27%) As of 03/25/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Actinium Pharmaceuticals (NYSE:ATNM) Earns "Buy" Rating from HC WainwrightMarch 26 at 2:25 AM | americanbankingnews.comActinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated Actimab-A Solid Tumor ProgramMarch 25 at 6:00 AM | prnewswire.comActinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development ActivitiesMarch 24 at 4:15 PM | prnewswire.comAnalysts Offer Insights on Healthcare Companies: Actinium Pharmaceuticals (ATNM) and Tonix Pharma (TNXP)March 21, 2025 | markets.businessinsider.comActinium Advances Actimab-A Trials In Combination With PD-1 Inhibitors For Solid TumorsMarch 20, 2025 | nasdaq.comActinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A's Backbone Therapy StrategyMarch 20, 2025 | prnewswire.comActinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-A and Iomab-ACT with Clinical Data in 2H:2025March 19, 2025 | prnewswire.comActinium Pharmaceuticals' (ATNM) Buy Rating Reiterated at HC WainwrightMarch 19, 2025 | americanbankingnews.comActinium Pharmaceuticals launches clinical trial for Actimab-A in combinationMarch 18, 2025 | markets.businessinsider.comActinium Pharmaceuticals Announces Clinical Trial Program in Solid Tumors Combining Actimab-A with PD-1 Checkpoint Inhibitors KEYTRUDA® and OPDIVO®March 18, 2025 | prnewswire.comActinium Pharmaceuticals reports Actimab-A + CLAG-M trial resultsMarch 17, 2025 | markets.businessinsider.comActinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal LeukemiaMarch 17, 2025 | prnewswire.comActinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives $7.40 Average Price Target from AnalystsMarch 16, 2025 | americanbankingnews.comActinium Pharmaceuticals to Participate at the 37th Annual Roth ConferenceMarch 12, 2025 | prnewswire.comActinium Pharmaceuticals initiates Actimab-A Triplet combination frontline trialMarch 12, 2025 | markets.businessinsider.comActinium Pharmaceuticals Announces Initiation of Actimab-A Triplet Combination Frontline Trial Under NCI CRADA with Venetoclax and Taiho Oncology's Hypomethylating Agent ASTX-727 in Patients with Newly Diagnosed AMLMarch 11, 2025 | prnewswire.comActinium Pharmaceuticals stock hits 52-week low at $1.1February 11, 2025 | msn.comH.C. Wainwright Sticks to Their Buy Rating for Actinium Pharmaceuticals (ATNM)January 23, 2025 | markets.businessinsider.comActinium Pharmaceuticals 2024 Stockholder Meeting OutcomesNovember 27, 2024 | markets.businessinsider.comActinium Pharmaceuticals Continues R&D Focus Amid Financial ProgressNovember 19, 2024 | markets.businessinsider.comActinium highlights development updates for Iomab-B, Actimab-A, Iomab-ACTNovember 18, 2024 | markets.businessinsider.comSK Biopharmaceuticals Seals 1st Actinium-225-Based Collaborative Research Agreement with Korea Institute of Radiological and Medical Sciences as Steps Toward Becoming Global Radiopharmaceutical Therapy PlayerNovember 18, 2024 | prnewswire.comActinium Pharma Q3 Loss NarrowsNovember 18, 2024 | markets.businessinsider.comActinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024November 18, 2024 | prnewswire.comOptimistic Buy Rating for Actinium Pharmaceuticals Driven by Strategic Progress and Promising PipelineNovember 15, 2024 | markets.businessinsider.comEQS-Adhoc: Eckert & Ziegler and Telix Pharmaceuticals Enter into a Collaboration and Licence Agreement for Actinium-225November 13, 2024 | markets.businessinsider.comActinium Pharmaceuticals, Inc. (NYSE:ATNM) Given Consensus Recommendation of "Moderate Buy" by BrokeragesActinium Pharmaceuticals, Inc. (NYSE:ATNM - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the five brokerages that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and four have given a buy recommendatioNovember 12, 2024 | marketbeat.comActinium Pharmaceuticals Strengthens Board with New AppointmentNovember 7, 2024 | markets.businessinsider.comActinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of DirectorsNovember 4, 2024 | finance.yahoo.comBoomi Honored with 2024 API Award for Best in iPaaSOctober 14, 2024 | msn.comArthur D. Little: The New "Telecom" – an Industry Alliance Forms to Fast-Track Network API MonetizationOctober 14, 2024 | finance.yahoo.comHow to Enable Camera2 API on Android? (ROOT & NO ROOT)October 13, 2024 | msn.comTelecom API Industry Assessment (2024-2032) by Type, User, Deployment, Industry Vertical, Region and Company - A Projected $1.24 Trillion LandscapeOctober 12, 2024 | finance.yahoo.comActinium Pharma (AMEX:ATNM) Stock, Short Interest ReportOctober 10, 2024 | benzinga.comBiocon shares in focus after issues 4 observations for Bengaluru API facilitySeptember 30, 2024 | msn.comBiocon gets Four observations from USFDA following Bengaluru API facilitySeptember 29, 2024 | msn.comSan Francisco API community hosts mayoral candidate townhallSeptember 28, 2024 | msn.comSan Francisco API community hosts mayoral candiate townhallSeptember 27, 2024 | msn.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc. - ATNMSeptember 25, 2024 | prnewswire.com'API prices/ volume growth to remain weak in FY25'September 25, 2024 | msn.comDrug API Market Research - Global Forecasts from 2024 to 2029: Favorable Investment & Collaboration in Biological Drugs Boosting GrowthSeptember 25, 2024 | finance.yahoo.comOpenAI casts its AI net wider across low-income countries with $1 million in API credits through its new OpenAI Academy initiativeSeptember 23, 2024 | msn.comLVT Releases API To Bring Video Security Intelligence To Any Software EcosystemSeptember 23, 2024 | markets.businessinsider.comWhy Every Business Needs an API: Unlocking New Revenue Streams and EfficiencySeptember 23, 2024 | msn.comDotPe leaves API public, exposes sensitive data of top restaurantsSeptember 23, 2024 | msn.comActinium Pharmaceuticals reports data from Phase III trial of AML treatmentSeptember 23, 2024 | finance.yahoo.comActinium Pharmaceuticals, Inc. (NYSE:ATNM) Given Average Rating of "Moderate Buy" by BrokeragesActinium Pharmaceuticals, Inc. (NYSE:ATNM - Get Free Report) has earned an average rating of "Moderate Buy" from the five research firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rSeptember 23, 2024 | marketbeat.comActinium Announces Publication Of Phase 3 SIERRA Results Of Iomab-B - Quick FactsSeptember 21, 2024 | markets.businessinsider.comLeading API biologics (cell, gene, vaccine and virus) companies in contract manufacturingSeptember 20, 2024 | finance.yahoo.comActinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical OncologySeptember 20, 2024 | finance.yahoo.com Remove Ads Get Actinium Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ATNM and its competitors with MarketBeat's FREE daily newsletter. Email Address ATNM Media Mentions By Week ATNM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATNM News Sentiment▼0.040.77▲Average Medical News Sentiment ATNM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATNM Articles This Week▼83▲ATNM Articles Average Week Remove Ads Get Actinium Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ATNM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Kodiak Sciences News Canopy Growth News Aclaris Therapeutics News Rezolute News 4D Molecular Therapeutics News Alumis News MediWound News Genfit News Acrivon Therapeutics News Fulcrum Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:ATNM) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actinium Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Actinium Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
